Sun Pharma, Philogen enter exclusive licensing pact for commercialisation of specialty cancer drug Firbomun

Sun Pharma has signed a global licensing deal with Philogen to commercialize Fibromun, an anti-cancer treatment currently in trial for soft tissue sarcoma and glioblastoma. Philogen will complete clinical trials and seek marketing authorization, while Sun Pharma will handle commercialization. Post-commercialization profits will be shared between both companies.